Navigation Links
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Date:8/3/2009

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results.

The webcast can be accessed on the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
3. OncoGenex Pharmaceuticals Added to Russell Indexes
4. OncoGenex Pharmaceuticals Files Shelf Registration Statement
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
8. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
9. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
10. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... never heard of "graphene" before, you might know something about ... announcements. Two physicists at the University of Manchester (UK) ... regarding the two-dimensional material graphene," carbon flakes that are only ... steel and as conductive as copper. But, what happens ...
... Oct. 13 Osteotech, Inc. (Nasdaq: OSTE ... products for regenerative healing, announced today that it has ... Trade Commission granted early termination of the Hart-Scott-Rodino waiting ... closing of the merger remains subject to antitrust clearance ...
... Today From a Preventable Lung Disease -- LONDON, October 14, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Beyond the Nobel Prize, what's next for graphene? 2Osteotech Announces Early Termination of HSR Waiting Period 2550 People Across Europe Will Die Today From a Preventable Lung Disease 2550 People Across Europe Will Die Today From a Preventable Lung Disease 3550 People Across Europe Will Die Today From a Preventable Lung Disease 4550 People Across Europe Will Die Today From a Preventable Lung Disease 5550 People Across Europe Will Die Today From a Preventable Lung Disease 6550 People Across Europe Will Die Today From a Preventable Lung Disease 7550 People Across Europe Will Die Today From a Preventable Lung Disease 8550 People Across Europe Will Die Today From a Preventable Lung Disease 9
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 2011) - A new study has found that most patients ... recommended number of samples to diagnose celiac disease. The ... Endoscopy , analyzed a national database of biopsy specimens maintained ... patients had a biopsy of the small intestine, but only ...
... leaves can vary by a factor of 1,000 across plant species, ... new study by an international team of scientists led by UCLA ... In research federally funded by the National Science Foundation, the ... to dry soil because of their distinct vein systems. ...
... The Damon Runyon Cancer Research Foundation, a ... researchers, named 18 new Damon Runyon Fellows at ... recipients of this prestigious, three-year award are outstanding ... in the laboratories of leading senior investigators across ...
Cached Biology News:Low adherence to biopsy guidelines affects celiac disease diagnosis in the United States 2Being small has its advantages, if you are a leaf 2Being small has its advantages, if you are a leaf 3Being small has its advantages, if you are a leaf 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6
... Mouse P815 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... Streptavidin-HRP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
Biology Products: